CN1895270A - 抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 - Google Patents
抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 Download PDFInfo
- Publication number
- CN1895270A CN1895270A CN 200610089493 CN200610089493A CN1895270A CN 1895270 A CN1895270 A CN 1895270A CN 200610089493 CN200610089493 CN 200610089493 CN 200610089493 A CN200610089493 A CN 200610089493A CN 1895270 A CN1895270 A CN 1895270A
- Authority
- CN
- China
- Prior art keywords
- health
- oxygen
- potassium
- care
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 239000001301 oxygen Substances 0.000 title claims abstract description 62
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 62
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 18
- 206010002660 Anoxia Diseases 0.000 title claims abstract description 12
- 241000976983 Anoxia Species 0.000 title claims abstract description 12
- 230000007953 anoxia Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 230000036039 immunity Effects 0.000 claims abstract description 6
- 239000008367 deionised water Substances 0.000 claims abstract description 5
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 8
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 8
- 229960002218 sodium chlorite Drugs 0.000 claims description 8
- 230000001706 oxygenating effect Effects 0.000 claims description 7
- 239000011736 potassium bicarbonate Substances 0.000 claims description 7
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 7
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- 235000011181 potassium carbonates Nutrition 0.000 claims description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 235000017550 sodium carbonate Nutrition 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000002929 anti-fatigue Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 7
- 229910052700 potassium Inorganic materials 0.000 abstract description 7
- 239000011591 potassium Substances 0.000 abstract description 7
- 229910052708 sodium Inorganic materials 0.000 abstract description 7
- 239000011734 sodium Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 229910001919 chlorite Inorganic materials 0.000 abstract description 4
- 229910052619 chlorite group Inorganic materials 0.000 abstract description 4
- 229940034610 toothpaste Drugs 0.000 abstract description 4
- 239000000606 toothpaste Substances 0.000 abstract description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000008213 purified water Substances 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000004868 gas analysis Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- -1 oxygen ion Chemical class 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量,mg/KgBW | 动物数,只 | 负重游泳时间,分 |
空白对照大剂量组中剂量组小剂量组阳性对照 | -10.50.253.3 | 1010101010 | 3.8±0.905.8±1.93*5.9±1.31**5.3±1.404.7±1.37 |
组别 | 剂量,mg/KgBW | 动物数,只 | 存活时间,分 |
空白对照大剂量组中剂量组小剂量组阳性对照 | -10.50.253.3 | 1010101010 | 21.4±1.5327.8±1.74***26.2±2.84***22.3±2.9722.2±1.88 |
组别 | 剂量,mg/KgBW | 动物数,只 | 喘气时间,秒 |
空白对照大剂量组中剂量组小剂量组阳性对照 | -10.50.253.3 | 1010101010 | 14.0±0.9017.1±1.33***18.2±1.07***18.6±0.61***17.7±2.18*** |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100894936A CN100522181C (zh) | 2006-06-30 | 2006-06-30 | 抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100894936A CN100522181C (zh) | 2006-06-30 | 2006-06-30 | 抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1895270A true CN1895270A (zh) | 2007-01-17 |
CN100522181C CN100522181C (zh) | 2009-08-05 |
Family
ID=37608007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100894936A Active CN100522181C (zh) | 2006-06-30 | 2006-06-30 | 抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100522181C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010363A (zh) * | 2017-06-08 | 2018-12-18 | 卢海元 | 一种艾滋病病毒分子靶向免疫氧疗药物及其制备方法 |
CN112168841A (zh) * | 2019-07-05 | 2021-01-05 | 卢序 | 一种增加人一氧化氮生物利用度的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3213389A1 (de) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
US4851222A (en) * | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
CN1191995C (zh) * | 2003-05-23 | 2005-03-09 | 秦瑞 | 含活性氧的液体的生产方法 |
-
2006
- 2006-06-30 CN CNB2006100894936A patent/CN100522181C/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010363A (zh) * | 2017-06-08 | 2018-12-18 | 卢海元 | 一种艾滋病病毒分子靶向免疫氧疗药物及其制备方法 |
CN112168841A (zh) * | 2019-07-05 | 2021-01-05 | 卢序 | 一种增加人一氧化氮生物利用度的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100522181C (zh) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
CN101036515A (zh) | 一种体力恢复保健食品及其制备方法 | |
CN1736270A (zh) | 解酒保肝饮料及其制备方法 | |
CN1871948A (zh) | 一种运动饮料及其制造方法 | |
CN102421446A (zh) | 含花楸提取物并含有硒和/或锌添加的免疫刺激组合物 | |
CN1064849C (zh) | 一种补血药剂的制备方法 | |
CN100522181C (zh) | 抗缺氧抗疲劳的健体氧及其制备方法和作为保健品的应用 | |
CN1733146A (zh) | 苦味清咽润喉含片 | |
CN109475513A (zh) | 提升运动能力的能量组合物 | |
CN1649601A (zh) | 含双果糖酐的组合物及其用途 | |
CN1097093A (zh) | 鹰嘴豆面制品及其加工方法 | |
US20060257503A1 (en) | Nutritional supplement and method for providing supplemental nutrition to an athlete | |
CN1819776A (zh) | 以活酵母菌为组分的液剂的制备方法及该液剂 | |
CN1218718C (zh) | 一种治疗支气管哮喘及急、慢性支气管炎的药物及其制备方法 | |
CN1840008A (zh) | 一种能清咽润喉的中药颗粒及其制备方法 | |
CN1207055C (zh) | 冬虫夏草生物活性多维强化剂的制备方法 | |
CN102908334A (zh) | 一种含氧胶囊 | |
CN1923210A (zh) | 含双果糖酐的组合物及其用途 | |
CN107637734A (zh) | 一种调理“三高”肽与哈密瓜果汁复配的肽果汁及其制备方法 | |
CN1640408A (zh) | 多功能抗病毒含片 | |
CN1261103C (zh) | 一种抗癌用微生物原料药、其生产方法及其用途 | |
CN1560216A (zh) | 一种蜂蜜蜂花粉酒及其制备方法 | |
CN1899056A (zh) | 一种桑叶奶及其制备方法与应用 | |
CN1515193A (zh) | 高级醇饮料 | |
CN107281200B (zh) | 一种含1,6-二磷酸果糖的复方固体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WANG XILIN Free format text: FORMER OWNER: SHANGDAOFANG SCIENCE AND TECHNOLOGY DEVELOPMENT (BEIJING) CO., LTD. Effective date: 20100906 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100095 NO.4-203, NO.408, TAIZHOUWU, WENQUAN TOWN, HAIDIAN DISTRICT, BEIJING TO: 100084 12-243, NORTHWEST RESIDENTIAL QUARTER, TSINGHUA UNIVERSITY, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100906 Address after: 100084 Northwest District of Tsinghua University, Beijing 12-243 Patentee after: Wang Xilin Address before: 100095, Beijing, Haidian District hot springs town, 408, No. 4-203 dock Patentee before: Thindo Fang technology development (Beijing) Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: LV SHIGUANG CHEN ZHANGHAI |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111111 Address after: 100084 Northwest District of Tsinghua University, Beijing 12-243 Co-patentee after: Lv Shiguang Patentee after: Wang Xilin Co-patentee after: Chen Changhai Address before: 100084 Northwest District of Tsinghua University, Beijing 12-243 Patentee before: Wang Xilin |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LV SHIGUANG CHEN CHANGHAI Effective date: 20150716 Owner name: TIBET SHENQUAN YIKANG INVESTMENT CO., LTD. Free format text: FORMER OWNER: WANG XILIN Effective date: 20150716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150716 Address after: Along the road 850000 Tibet autonomous region quxur County, Lhasa City Industrial Park, No. 4 Patentee after: Tibet sqyk investment Limited by Share Ltd Address before: 100084 Northwest District of Tsinghua University, Beijing 12-243 Patentee before: Wang Xilin Patentee before: Lv Shiguang Patentee before: Chen Changhai |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20190424 Granted publication date: 20090805 |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20220424 Granted publication date: 20090805 |
|
PD01 | Discharge of preservation of patent | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20220427 Granted publication date: 20090805 |